However, Wu et al. reported that osimertinib demonstrated statistically longer disease-free survival in patients with stage IB to IIIA EGFR-mutated NSCLC than in those who received a placebo [15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.